Certara, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter earnings report; the supplied filing text does not provide a complete Q4 income statement. All financial amounts below are U.S. dollars.
Business context
Certara provides biosimulation software and technology-enabled services for the biopharmaceutical industry, supporting model-informed drug development, regulatory submissions and related activities. Its strategy emphasizes software development, AI-enabled offerings, customer expansion and acquisitions. In 2023, it launched 32 software applications and upgrades and acquired Drug Interaction Solutions, Formedix and Applied Biomath.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Revenue | $354.3 million | $335.6 million | Up 6% |
| Software revenue | $131.7 million | $115.5 million | Up 14% |
| Services revenue | $222.7 million | $220.2 million | Up 1% |
| Gross profit / gross margin | $213.3 million / about 60.2% | $203.1 million / about 60.5% | Margin slightly lower |
| Operating income (loss) | $(40.8) million | $32.5 million | Operating margin: about (11.5)% vs. 9.7% |
| Net income (loss) | $(55.4) million | $14.7 million | Diluted EPS: $(0.35) vs. $0.09 |
| Adjusted EBITDA (non-GAAP) | $123.1 million | $120.2 million | Up about 2%; see filing reconciliation |
| Operating cash flow | $82.8 million | $92.5 million | Down $9.8 million |
| Cash and cash equivalents at year-end | $235.0 million | $236.6 million | Down $1.6 million |
| Term debt outstanding | $294.5 million | $297.5 million | $100 million revolver available; none drawn |
Revenue growth reflected software demand, product introductions and customer expansion; services growth was primarily in biosimulation and partly offset by lower regulatory services. Cash used in investing activities was $79.6 million, including $64.2 million for acquisitions and $13.5 million in capitalized software development. Year-end cash less term borrowings implies net debt of approximately $59.5 million.
Material changes and unusual items
- FY2023 net loss included a $47.0 million goodwill impairment charge for the regulatory-writing reporting unit, following lower revenue and profitability forecasts and reduced demand from certain customer groups.
- General and administrative expense included a $24.1 million increase in expense from remeasurement of acquisition-related contingent consideration. Total contingent consideration liabilities were $54.5 million at year-end; valuations depend on acquired businesses meeting revenue targets and other conditions.
- Interest expense rose 29% to $22.9 million, primarily due to higher market rates on floating-rate debt, partly offset by interest-rate swap activity. The reported effective interest rate on the credit agreement was 8.84% for 2023.
- Bookings were $402.3 million, down from $409.0 million in 2022. The annual software renewal rate was 88%, compared with 91% in 2022; the technology-enabled services net revenue repeat rate was 96%.
- For Q4 specifically, bookings were $118.9 million versus $120.4 million in Q4 2022, and the software renewal rate was 85% versus 88%. These metrics do not substitute for quarterly financial results.
Outlook, risks and contingencies
The filing gives no specific numerical revenue or earnings guidance. Management expects continued investment in scientific talent, sales and marketing, R&D and operations, and says operating expenses and headcount are expected to increase over time. Management believes existing liquidity will cover working capital, capital expenditures and contractual obligations for the foreseeable future.
Key risks include customer reductions or delays in biopharmaceutical R&D spending; competition and adoption of biosimulation; customer renewals and contract cancellations; execution and integration of acquisitions; AI-related product, regulatory and liability risks; cybersecurity, privacy and cloud-provider disruptions; foreign-exchange exposure; and variable-rate debt and restrictive credit covenants. The ten largest customers represented 28% of revenue in both 2023 and 2022. The company reported no pending or threatened litigation expected to have a material adverse effect and no known cybersecurity incident with a material impact as of the filing date.
The financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting as of December 31, 2023. The auditor identified critical audit matters involving fixed-price contract revenue estimates, goodwill impairment valuation and valuations of acquired intangible assets and contingent consideration.
Important facts for investors to verify
- Whether software growth, renewal rates and bookings stabilize or improve, particularly given the Q4 renewal rate of 85% and slightly lower bookings.
- Whether the regulatory-writing business recovers from the demand weakness that drove the $47.0 million impairment.
- How acquisition performance compares with revenue thresholds underlying the $54.5 million contingent consideration liability, including potential future cash or share payments.
- Debt repayment capacity and interest-rate sensitivity: $294.5 million of term borrowings, variable-rate exposure, and a $230 million interest-rate swap scheduled to end in August 2025.
- The durability of cash generation as acquisition spending, operating costs and expected amortization continue; adjusted EBITDA is non-GAAP and excludes significant costs.
- Standalone Q4 revenue, profit, margins and cash flow, which are not clearly provided in the supplied filing text.